John Markels - 12 Jun 2025 Form 4 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)

Reporting relationship: Director
Issuer ticker: SGMO
Reported as of: 12 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Jun 2025, 16:05:13 UTC
Prior SEC filing: 11 Jun 2025
Next SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Prathyusha Duraibabu, Attorney-in-Fact

Key filing fact

John Markels filed Form 4 for SANGAMO THERAPEUTICS, INC (SGMO) on 16 Jun 2025.

Key facts

This page summarizes John Markels's Form 4 filing for SANGAMO THERAPEUTICS, INC (SGMO).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 16 Jun 2025, 16:05.

Change

Previous filing in this sequence was filed on 11 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001803424 Primary reporting owner

Markels John

Relationship: Director
Address: C/O SANGAMO THERAPEUTICS, INC., 501 CANAL BLVD., RICHMOND
Signature: /s/ Prathyusha Duraibabu, Attorney-in-Fact
Signature date: 16 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SGMO transaction

Common Stock

Award

Transaction value: $0
Shares: +25,000
Change %: +35%
Price: $0.000000
Shares after: 96,384
Date: 12 Jun 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SGMO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +50,000
Change %
Price: $0.000000
Shares after: 50,000
Date: 12 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $0.5030
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.

Footnote F2

The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.